

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 12:30:53

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C Number: C20310B
Lock Date: 04/20/2010
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Male
TDMSE Version: 2.2.0

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle | AZT 60 | 3TC 37.5 | NVP 10.5 | AZT 60 3TC 37.5 | A20,3T12.5,NV3.5 |
|---------------------------------------|---------|--------|----------|----------|-----------------|------------------|
|---------------------------------------|---------|--------|----------|----------|-----------------|------------------|

Disposition Summary

| | | | | | | |
|----------------------------------|----|----|----|----|----|----|
| Animals Initially In Study | 25 | 25 | 25 | 26 | 25 | 25 |
| Early Deaths | | | | | | |
| Moribund Sacrifice | 1 | 2 | | | 1 | |
| Natural Death | 1 | 1 | 1 | 4 | | |
| Survivors | | | | | | |
| Moribund Sacrifice | 1 | 2 | | | 2 | |
| Natural Death | 2 | 2 | 1 | | 1 | 1 |
| Terminal Sacrifice | 20 | 18 | 23 | 22 | 21 | 24 |
| Animals Examined Microscopically | 25 | 25 | 25 | 26 | 25 | 25 |

ALIMENTARY SYSTEM

| | | | | | | |
|-----------------------------------|----------|----------|----------|----------|----------|----------|
| Intestine Large, Cecum | (22) | (22) | (24) | (22) | (24) | (24) |
| Intestine Large, Colon | (22) | (22) | (25) | (23) | (24) | (24) |
| Intestine Large, Rectum | (22) | (22) | (23) | (22) | (24) | (24) |
| Intestine Small, Duodenum | (23) | (22) | (23) | (22) | (24) | (24) |
| Ectopic Pancreas | | | | | | |
| Intestine Small, Jejunum | (23) | (22) | (23) | (22) | (24) | (24) |
| Liver | (25) | (24) | (25) | (25) | (25) | (25) |
| Basophilic Focus | | | 1 (4%) | 1 (4%) | 1 (4%) | |
| Hematopoietic Cell Proliferation | 1 (4%) | | | | | 1 (4%) |
| Infiltration Cellular, Lymphocyte | | | | 1 (4%) | | 1 (4%) |
| Inflammation, Suppurative | | | | | | |
| Inflammation, Chronic Active | | | 1 (4%) | | 1 (4%) | 1 (4%) |
| Mixed Cell Focus | | | 1 (4%) | | 1 (4%) | |
| Necrosis | 1 (4%) | | 1 (4%) | | | 1 (4%) |
| Tension Lipidosis | | 1 (4%) | | 1 (4%) | 1 (4%) | 2 (8%) |
| Vacuolization Cytoplasmic | 19 (76%) | 18 (75%) | 20 (80%) | 20 (80%) | 21 (84%) | 21 (84%) |
| Centrilobular, Degeneration | 15 (60%) | 16 (67%) | 18 (72%) | 17 (68%) | 17 (68%) | 20 (80%) |
| Mesentery | (3) | (0) | (0) | (1) | (2) | (1) |
| Inflammation, Chronic Active | | | | | 1 (50%) | |
| Fat, Necrosis | 1 (33%) | | | | 1 (50%) | |
| Pancreas | (24) | (23) | (25) | (25) | (24) | (25) |
| Cyst | 1 (4%) | 1 (4%) | | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle | AZT 60 | 3TC 37.5 | NVP 10.5 | AZT 60 3TC 37.5 | A20,3T12.5,NV3.5 |
|-----------------------------------------------------------|----------|----------|----------|----------|-----------------|------------------|
| Hemorrhage | | | | | 1 (4%) | |
| Infiltration Cellular, Lymphocyte Acinus, Degeneration | | 1 (4%) | 1 (4%) | | 1 (4%) | 2 (8%) |
| Salivary Glands | (25) | (23) | (25) | (25) | (24) | (25) |
| Infiltration Cellular, Lymphocyte | 18 (72%) | 12 (52%) | 13 (52%) | 18 (72%) | 11 (46%) | 14 (56%) |
| Stomach, Forestomach | (25) | (23) | (25) | (23) | (24) | (25) |
| Hyperkeratosis | | 1 (4%) | | | | |
| Ulcer | | | | | 1 (4%) | |
| Epithelium, Hyperplasia | 1 (4%) | | | | 1 (4%) | |
| Stomach, Glandular | (23) | (22) | (24) | (22) | (24) | (24) |
| CARDIOVASCULAR SYSTEM | | | | | | |
| Blood Vessel | (25) | (24) | (25) | (25) | (24) | (25) |
| Heart | (25) | (25) | (25) | (25) | (24) | (25) |
| Mineralization | | | | | | 1 (4%) |
| ENDOCRINE SYSTEM | | | | | | |
| Adrenal Cortex | (25) | (24) | (25) | (25) | (23) | (25) |
| Accessory Adrenal Cortical Nodule | 1 (4%) | | | | | |
| Cyst | | | | | 1 (4%) | |
| Hypertrophy | | 1 (4%) | | | | |
| Subcapsular, Hyperplasia | 13 (52%) | 12 (50%) | 13 (52%) | 7 (28%) | 11 (48%) | 14 (56%) |
| Adrenal Medulla | (25) | (23) | (25) | (23) | (21) | (25) |
| Islets, Pancreatic | (24) | (24) | (25) | (25) | (24) | (25) |
| Hyperplasia | 13 (54%) | 10 (42%) | 15 (60%) | 10 (40%) | 14 (58%) | 9 (36%) |
| Parathyroid Gland | (23) | (21) | (24) | (18) | (19) | (23) |
| Cyst | | | 1 (4%) | | | |
| Pituitary Gland | (24) | (22) | (25) | (25) | (24) | (25) |
| Thyroid Gland | (25) | (23) | (25) | (23) | (23) | (25) |
| Ectopic Thymus | 2 (8%) | | 1 (4%) | | | |
| Follicle, Degeneration | | | | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle | AZT 60 | 3TC 37.5 | NVP 10.5 | AZT 60 3TC 37.5 | A20,3T12.5,NV3.5 |
|---------------------------------------|---------|---------|----------|----------|-----------------|------------------|
| GENERAL BODY SYSTEM | | | | | | |
| Tissue NOS | (1) | (0) | (1) | (3) | (0) | (0) |
| Abscess | | | | 1 (33%) | | |
| Abdominal, Fat, Necrosis | | | 1 (100%) | | | |
| GENITAL SYSTEM | | | | | | |
| Epididymis | (25) | (23) | (25) | (25) | (24) | (25) |
| Exfoliated Germ Cell | | 1 (4%) | | | | |
| Hypospermia | | | | | | |
| Inflammation, Chronic Active | | | | | | |
| Preputial Gland | (25) | (24) | (25) | (25) | (24) | (25) |
| Cyst | | | | | | 1 (4%) |
| Infiltration Cellular, Lymphocyte | | | 1 (4%) | | | 1 (4%) |
| Infiltration Cellular, Plasma Cell | | 1 (4%) | | | | |
| Inflammation, Suppurative | | 1 (4%) | | | | |
| Inflammation, Chronic Active | 1 (4%) | 1 (4%) | | | | |
| Keratin Cyst | | | | | | 1 (4%) |
| Acinus, Degeneration | 3 (12%) | 2 (8%) | 3 (12%) | 3 (12%) | 1 (4%) | 4 (16%) |
| Duct, Ectasia | 3 (12%) | 2 (8%) | 2 (8%) | 4 (16%) | 1 (4%) | 3 (12%) |
| Prostate | (25) | (23) | (25) | (25) | (24) | (25) |
| Infiltration Cellular, Lymphocyte | | | 1 (4%) | | | |
| Inflammation, Suppurative | | | 1 (4%) | | | |
| Seminal Vesicle | (25) | (23) | (24) | (25) | (24) | (25) |
| Testes | (25) | (24) | (24) | (25) | (24) | (25) |
| Seminiferous Tubule, Degeneration | | 1 (4%) | 1 (4%) | 2 (8%) | | |
| HEMATOPOIETIC SYSTEM | | | | | | |
| Bone Marrow | (23) | (24) | (24) | (25) | (24) | (25) |
| Hyperplasia | 3 (13%) | 3 (13%) | 1 (4%) | 2 (8%) | 2 (8%) | 2 (8%) |
| Lymph Node | (2) | (2) | (1) | (1) | (2) | (3) |
| Axillary, Hyperplasia, Lymphoid | | | | | | 1 (33%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 12:30:53

First Dose M/F: 12/22/06 / NA

Lab: NCTR

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle | AZT 60 | 3TC 37.5 | NVP 10.5 | AZT 60 3TC 37.5 | A20,3T12.5,NV3.5 |
|-------------------------------------------------|----------|----------|----------|----------|-----------------|------------------|
| Lumbar, Hyperplasia, Lymphoid | | | | | | 1 (33%) |
| Mediastinal, Hyperplasia, Lymphoid | 1 (50%) | | | 1 (100%) | | 2 (67%) |
| Mediastinal, Infiltration Cellular, Plasma Cell | | | | | | 1 (33%) |
| Renal, Hyperplasia, Lymphoid | | | | | | 1 (33%) |
| Lymph Node, Mandibular | (25) | (23) | (25) | (25) | (24) | (25) |
| Hyperplasia, Lymphoid | 2 (8%) | 1 (4%) | 2 (8%) | 2 (8%) | 2 (8%) | 2 (8%) |
| Infiltration Cellular, Plasma Cell | | | | | | |
| Lymph Node, Mesenteric | (24) | (23) | (25) | (25) | (24) | (25) |
| Congestion | | 1 (4%) | | | | |
| Hyperplasia, Lymphoid | 9 (38%) | 5 (22%) | 12 (48%) | 11 (44%) | 11 (46%) | 10 (40%) |
| Infiltration Cellular, Plasma Cell | | | 1 (4%) | 2 (8%) | 1 (4%) | 1 (4%) |
| Infiltration Cellular, Polymorphonuclear | | | | | | |
| Spleen | (25) | (23) | (24) | (25) | (24) | (25) |
| Congestion | | | | | 1 (4%) | |
| Hematopoietic Cell Proliferation | 7 (28%) | 11 (48%) | 4 (17%) | 5 (20%) | 11 (46%) | 9 (36%) |
| Hyperplasia, Lymphoid | 12 (48%) | 14 (61%) | 16 (67%) | 18 (72%) | 14 (58%) | 15 (60%) |
| Thymus | (24) | (22) | (24) | (23) | (22) | (25) |
| Atrophy | 2 (8%) | 1 (5%) | | 1 (4%) | 1 (5%) | 1 (4%) |
| Cyst | | 1 (5%) | | | | |
| Hyperplasia, Lymphoid | 2 (8%) | | | 1 (4%) | 3 (14%) | 3 (12%) |
| INTEGUMENTARY SYSTEM | | | | | | |
| Skin | (25) | (25) | (25) | (25) | (24) | (25) |
| Cyst | | 1 (4%) | | | | |
| Granuloma | | 1 (4%) | | | | |
| Inflammation, Suppurative | | | | | | |
| Epithelium, Hyperplasia | | | | | | |
| MUSCULOSKELETAL SYSTEM | | | | | | |
| Bone | (3) | (1) | (1) | (1) | (0) | (0) |
| Bone, Femur | (25) | (25) | (25) | (25) | (25) | (25) |
| Fibro-Osseous Lesion | 1 (4%) | | | | | |
| Skeletal Muscle | (3) | (2) | (1) | (0) | (0) | (0) |

a - Number of animals examined microscopically at site and number of animals with lesion

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle | AZT 60 | 3TC 37.5 | NVP 10.5 | AZT 60 3TC 37.5 | A20,3T12.5,NV3.5 |
|---------------------------------------|----------|---------|----------|----------|-----------------|------------------|
| NERVOUS SYSTEM | | | | | | |
| Brain, Brain Stem | (25) | (24) | (25) | (25) | (24) | (24) |
| Brain, Cerebellum | (25) | (24) | (25) | (25) | (24) | (24) |
| Compression | | | 1 (4%) | | | |
| Hemorrhage | | 1 (4%) | | | | |
| Brain, Cerebrum | (25) | (24) | (25) | (25) | (24) | (25) |
| Mineralization | 2 (8%) | 3 (13%) | 4 (16%) | 4 (16%) | 2 (8%) | 1 (4%) |
| Spinal Cord, Thoracic | (1) | (0) | (0) | (0) | (0) | (0) |
| Compression | 1 (100%) | | | | | |
| RESPIRATORY SYSTEM | | | | | | |
| Lung | (25) | (24) | (25) | (25) | (24) | (25) |
| Hemorrhage | | 1 (4%) | | | 1 (4%) | 1 (4%) |
| Infiltration Cellular, Histiocyte | | 1 (4%) | 1 (4%) | | | |
| Inflammation, Chronic | | | | 1 (4%) | | |
| Mineralization | | 1 (4%) | | 1 (4%) | | |
| Alveolar Epithelium, Hyperplasia | | | | 1 (4%) | | 1 (4%) |
| Nose | (25) | (25) | (25) | (25) | (25) | (25) |
| Hyaline Droplet | | | 1 (4%) | | 2 (8%) | 3 (12%) |
| SPECIAL SENSES SYSTEM | | | | | | |
| Eye | (22) | (22) | (23) | (23) | (24) | (24) |
| Inflammation, Chronic Active | | 1 (5%) | | | | |
| Cornea, Ulcer | | 1 (5%) | | | | |
| Harderian Gland | (25) | (22) | (25) | (25) | (24) | (25) |
| Infiltration Cellular, Lymphocyte | 1 (4%) | | | | | 1 (4%) |
| URINARY SYSTEM | | | | | | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 12:30:53

First Dose M/F: 12/22/06 / NA

Lab: NCTR

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle | AZT 60 | 3TC 37.5 | NVP 10.5 | AZT 60 3TC 37.5 | A20,3T12.5,NV3.5 |
|---------------------------------------|---------|---------|----------|----------|-----------------|------------------|
| Kidney | (25) | (24) | (25) | (25) | (24) | (25) |
| Casts Protein | 3 (12%) | 5 (21%) | 6 (24%) | 7 (28%) | 8 (33%) | 7 (28%) |
| Cyst | | | | | | |
| Hemorrhage | | | | 1 (4%) | | |
| Hydronephrosis | 1 (4%) | 8 (33%) | 7 (28%) | 5 (20%) | 9 (38%) | 13 (52%) |
| Infarct | | | | | | |
| Infiltration Cellular, Lymphocyte | 8 (32%) | 2 (8%) | 10 (40%) | 6 (24%) | 2 (8%) | 9 (36%) |
| Metaplasia, Osseous | | | 1 (4%) | | 1 (4%) | |
| Nephropathy | 1 (4%) | 1 (4%) | 2 (8%) | | | |
| Renal Tubule, Regeneration | | | 1 (4%) | | | |
| Transitional Epithelium, Hyperplasia | | | 1 (4%) | | | |
| Urinary Bladder | (25) | (24) | (25) | (25) | (24) | (25) |
| Hemorrhage | | | | | 1 (4%) | |
| Infiltration Cellular, Histiocyte | | | | 1 (4%) | | |
| Infiltration Cellular, Lymphocyte | 2 (8%) | | | 2 (8%) | 1 (4%) | 1 (4%) |
| Lumen, Dilatation | 1 (4%) | 1 (4%) | 1 (4%) | 1 (4%) | | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 12:30:53

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

AZT40,3TC25,NVP7

A60,3T37.5,N10.5

Disposition Summary

| | | |
|----------------------------------|----|----|
| Animals Initially In Study | 25 | 25 |
| Early Deaths | | |
| Moribund Sacrifice | | |
| Natural Death | | 1 |
| Survivors | | |
| Moribund Sacrifice | 1 | 1 |
| Natural Death | | |
| Terminal Sacrifice | 24 | 23 |
| Animals Examined Microscopically | 23 | 24 |

ALIMENTARY SYSTEM

| | | |
|-----------------------------------|----------|----------|
| Intestine Large, Cecum | (23) | (23) |
| Intestine Large, Colon | (23) | (23) |
| Intestine Large, Rectum | (23) | (23) |
| Intestine Small, Duodenum | (23) | (23) |
| Ectopic Pancreas | | 1 (4%) |
| Intestine Small, Jejunum | (23) | (23) |
| Liver | (23) | (23) |
| Basophilic Focus | 2 (9%) | 2 (9%) |
| Hematopoietic Cell Proliferation | | |
| Infiltration Cellular, Lymphocyte | 1 (4%) | |
| Inflammation, Suppurative | 1 (4%) | |
| Inflammation, Chronic Active | 1 (4%) | 1 (4%) |
| Mixed Cell Focus | | |
| Necrosis | 1 (4%) | 2 (9%) |
| Tension Lipidosis | 2 (9%) | 1 (4%) |
| Vacuolization Cytoplasmic | 19 (83%) | 20 (87%) |
| Centrilobular, Degeneration | 18 (78%) | 17 (74%) |
| Mesentery | (2) | (0) |
| Inflammation, Chronic Active | | |
| Fat, Necrosis | 2 (100%) | |
| Pancreas | (23) | (23) |
| Cyst | | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 12:30:53

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE AZT40,3TC25,NVP7 A60,3T37.5,N10.5

| | | |
|-----------------------------------|----------|----------|
| Hemorrhage | | |
| Infiltration Cellular, Lymphocyte | | |
| Acinus, Degeneration | 1 (4%) | |
| Salivary Glands | (23) | (23) |
| Infiltration Cellular, Lymphocyte | 16 (70%) | 16 (70%) |
| Stomach, Forestomach | (23) | (23) |
| Hyperkeratosis | 1 (4%) | |
| Ulcer | | |
| Epithelium, Hyperplasia | | |
| Stomach, Glandular | (23) | (23) |

CARDIOVASCULAR SYSTEM

| | | |
|----------------|------|------|
| Blood Vessel | (23) | (24) |
| Heart | (23) | (24) |
| Mineralization | | |

ENDOCRINE SYSTEM

| | | |
|-----------------------------------|----------|----------|
| Adrenal Cortex | (23) | (23) |
| Accessory Adrenal Cortical Nodule | | 1 (4%) |
| Cyst | | |
| Hypertrophy | 1 (4%) | 2 (9%) |
| Subcapsular, Hyperplasia | 11 (48%) | 12 (52%) |
| Adrenal Medulla | (23) | (22) |
| Islets, Pancreatic | (23) | (23) |
| Hyperplasia | 13 (57%) | 6 (26%) |
| Parathyroid Gland | (23) | (23) |
| Cyst | | |
| Pituitary Gland | (23) | (23) |
| Thyroid Gland | (23) | (23) |
| Ectopic Thymus | | |
| Follicle, Degeneration | | 1 (4%) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 12:30:53

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

AZT40,3TC25,NVP7

A60,3T37.5,N10.5

GENERAL BODY SYSTEM

| | | |
|--------------------------|-----|-----|
| Tissue NOS | (0) | (0) |
| Abscess | | |
| Abdominal, Fat, Necrosis | | |

GENITAL SYSTEM

| | | |
|------------------------------------|---------|---------|
| Epididymis | (23) | (23) |
| Exfoliated Germ Cell | | 1 (4%) |
| Hypospermia | | 1 (4%) |
| Inflammation, Chronic Active | 1 (4%) | |
| Preputial Gland | (23) | (23) |
| Cyst | | |
| Infiltration Cellular, Lymphocyte | | |
| Infiltration Cellular, Plasma Cell | | |
| Inflammation, Suppurative | 1 (4%) | |
| Inflammation, Chronic Active | 1 (4%) | |
| Keratin Cyst | | |
| Acinus, Degeneration | 7 (30%) | 5 (22%) |
| Duct, Ectasia | 5 (22%) | 5 (22%) |
| Prostate | (23) | (23) |
| Infiltration Cellular, Lymphocyte | | |
| Inflammation, Suppurative | 1 (4%) | |
| Seminal Vesicle | (23) | (23) |
| Testes | (23) | (23) |
| Seminiferous Tubule, Degeneration | 1 (4%) | 1 (4%) |

HEMATOPOIETIC SYSTEM

| | | |
|---------------------------------|---------|------|
| Bone Marrow | (23) | (23) |
| Hyperplasia | 4 (17%) | |
| Lymph Node | (1) | (1) |
| Axillary, Hyperplasia, Lymphoid | | |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 12:30:53

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

AZT40,3TC25,NVP7

A60,3T37.5,N10.5

| | | |
|-------------------------------------------------|----------|----------|
| Lumbar, Hyperplasia, Lymphoid | | |
| Mediastinal, Hyperplasia, Lymphoid | | |
| Mediastinal, Infiltration Cellular, Plasma Cell | | |
| Renal, Hyperplasia, Lymphoid | | |
| Lymph Node, Mandibular | (23) | (23) |
| Hyperplasia, Lymphoid | 4 (17%) | 5 (22%) |
| Infiltration Cellular, Plasma Cell | 1 (4%) | |
| Lymph Node, Mesenteric | (23) | (23) |
| Congestion | | |
| Hyperplasia, Lymphoid | 5 (22%) | 9 (39%) |
| Infiltration Cellular, Plasma Cell | 1 (4%) | |
| Infiltration Cellular, Polymorphonuclear | 1 (4%) | |
| Spleen | (23) | (23) |
| Congestion | | |
| Hematopoietic Cell Proliferation | 6 (26%) | 6 (26%) |
| Hyperplasia, Lymphoid | 13 (57%) | 12 (52%) |
| Thymus | (20) | (20) |
| Atrophy | | 1 (5%) |
| Cyst | | |
| Hyperplasia, Lymphoid | 1 (5%) | 1 (5%) |

INTEGUMENTARY SYSTEM

| | | |
|---------------------------|------|--------|
| Skin | (23) | (24) |
| Cyst | | |
| Granuloma | | |
| Inflammation, Suppurative | | 1 (4%) |
| Epithelium, Hyperplasia | | 1 (4%) |

MUSCULOSKELETAL SYSTEM

| | | |
|----------------------|--------|------|
| Bone | (1) | (1) |
| Bone, Femur | (23) | (24) |
| Fibro-Osseous Lesion | 1 (4%) | |
| Skeletal Muscle | (0) | (0) |

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03
Test Type: 26-39 WEEKS

Route: GAVAGE
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT+3TC combination
CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 12:30:53

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

AZT40,3TC25,NVP7

A60,3T37.5,N10.5

NERVOUS SYSTEM

| | | |
|-----------------------|---------|--------|
| Brain, Brain Stem | (23) | (23) |
| Brain, Cerebellum | (23) | (23) |
| Compression | | |
| Hemorrhage | | |
| Brain, Cerebrum | (23) | (23) |
| Mineralization | 3 (13%) | 1 (4%) |
| Spinal Cord, Thoracic | (0) | (0) |
| Compression | | |

RESPIRATORY SYSTEM

| | | |
|-----------------------------------|--------|--------|
| Lung | (23) | (23) |
| Hemorrhage | | |
| Infiltration Cellular, Histiocyte | | |
| Inflammation, Chronic | | |
| Mineralization | | |
| Alveolar Epithelium, Hyperplasia | | 1 (4%) |
| Nose | (23) | (24) |
| Hyaline Droplet | 2 (9%) | |

SPECIAL SENSES SYSTEM

| | | |
|-----------------------------------|--------|------|
| Eye | (23) | (23) |
| Inflammation, Chronic Active | | |
| Cornea, Ulcer | | |
| Harderian Gland | (23) | (23) |
| Infiltration Cellular, Lymphocyte | 1 (4%) | |

URINARY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 12:30:53

First Dose M/F: 12/22/06 / NA

Lab: NCTR

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | AZT40,3TC25,NVP7 | A60,3T37.5,N10.5 |
|---------------------------------------|------------------|------------------|
| Kidney | (23) | (23) |
| Casts Protein | 7 (30%) | 10 (43%) |
| Cyst | 1 (4%) | |
| Hemorrhage | | |
| Hydronephrosis | 5 (22%) | 12 (52%) |
| Infarct | 1 (4%) | |
| Infiltration Cellular, Lymphocyte | 9 (39%) | 7 (30%) |
| Metaplasia, Osseous | | |
| Nephropathy | | 1 (4%) |
| Renal Tubule, Regeneration | | |
| Transitional Epithelium, Hyperplasia | | |
| Urinary Bladder | (23) | (23) |
| Hemorrhage | | |
| Infiltration Cellular, Histiocyte | | |
| Infiltration Cellular, Lymphocyte | 1 (4%) | 1 (4%) |
| Lumen, Dilatation | | |

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion